Syros Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYRS research report →
Companywww.syros.com
Syros Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
- CEO
- James E. Bradner
- IPO
- 2016
- Employees
- 68
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $5.37K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.49
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.33%
- Op Margin
- -1298.19%
- Net Margin
- -1656.34%
- ROE
- -227.94%
- ROIC
- -91.82%
Growth & Income
- Revenue
- $9.94M · -33.23%
- Net Income
- $-164,574,000 · -73.87%
- EPS
- $-5.81 · 22.43%
- Op Income
- $-128,988,000
- FCF YoY
- 11.53%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.26
- Avg Volume
- 10.93K
Get TickerSpark's AI analysis on SYRS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 24 | Simonian Nancy A | sell | 37,070 |
| Nov 25, 24 | Simonian Nancy A | sell | 134,713 |
| Nov 18, 24 | Stephens Kristin | sell | 36,133 |
| Nov 18, 24 | Roth David | sell | 12,099 |
| Nov 19, 24 | Quirk Gerald E | sell | 46,657 |
| Nov 18, 24 | Chee Conley | sell | 134,797 |
| Nov 18, 24 | Haas Jason | sell | 137,803 |
| Oct 31, 24 | Simonian Nancy A | other | 40,125 |
| Oct 31, 24 | Simonian Nancy A | other | 40,125 |
| Oct 31, 24 | Roth David | other | 18,875 |
Our SYRS Coverage
We haven't published any research on SYRS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SYRS Report →